Which statement about flumazenil use is accurate regarding practice scope?

• A. It is always part of standard practice
• B. It has no interactions
• C. It is a long-acting benzodiazepine
• D. It may not be part of national scope of practice

Answer: (D)

The key idea here is that whether flumazenil can be used depends on regulatory and institutional rules, not just pharmacology. Practices around reversal of benzodiazepines are not uniform worldwide; some national scopes of practice or hospital policies authorize it, others do not or require special approvals. That variability makes the statement about it possibly not being part of national scope the most accurate.

Flumazenil acts as a benzodiazepine receptor antagonist to reverse sedation, but its use is not universally standard. It carries risks such as precipitating withdrawal or seizures in patients with benzodiazepine dependence or in overdoses involving mixed substances, and its effect is relatively short-lived compared with some benzodiazepines, so re-sedation can occur if the benzo’s effects persist. It also has interactions and contraindications in certain clinical scenarios, so saying there are no interactions is incorrect. It is not a long-acting benzodiazepine; it’s an antagonist with a short duration of action.